High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma

被引：44

作者：

Aoki, T. ^{[1
,2
]}

Shimada, K. ^{[2
]}

Suzuki, R. ^{[3
]}

Izutsu, K. ^{[4
]}

Tomita, A. ^{[2
]}

Maeda, Y. ^{[5
]}

Takizawa, J. ^{[6
]}

Mitani, K. ^{[7
]}

Igarashi, T. ^{[8
]}

Sakai, K. ^{[9
,10
]}

Miyazaki, K. ^{[11
]}

Mihara, K. ^{[12
]}

Ohmachi, K. ^{[13
]}

Nakamura, N. ^{[14
]}

Takasaki, H. ^{[15
]}

Kiyoi, H. ^{[2
]}

Nakamura, S. ^{[16
,17
]}

Kinoshita, T. ^{[18
]}

Ogura, M. ^{[1
,19
]}

机构：

[1] Nagoya Daini Red Cross Hosp, Dept Hematol & Oncol, Nagoya, Aichi, Japan

[2] Nagoya Univ, Grad Sch Med, Dept Hematol & Oncol, Nagoya, Aichi 4648601, Japan

[3] Shimane Univ Hosp, Canc Ctr, Izumo, Shimane, Japan

[4] Toranomon Gen Hosp, Dept Hematol, Tokyo, Japan

[5] Okayama Univ Hosp, Dept Hematol & Oncol, Okayama, Japan

[6] Niigata Univ, Fac Med, Dept Hematol Endocrinol & Metab, Niigata, Japan

[7] Dokkyo Med Univ, Sch Med, Dept Hematol & Oncol, Mibu, Tochigi, Japan

[8] Gunma Canc Ctr, Dept Hematol & Oncol, Ota, Japan

[9] Shinshu Univ, Sch Med, Dept Biomed Lab Sci, Matsumoto, Nagano 390, Japan

[10] Shinshu Univ, Sch Med, Dept Hematol, Matsumoto, Nagano 390, Japan

[11] Mie Univ, Grad Sch Med, Dept Hematol & Oncol, Tsu, Mie 514, Japan

[12] Hiroshima Univ Hosp, Dept Hematol, Hiroshima, Japan

[13] Tokai Univ, Dept Hematol, Isehara, Kanagawa, Japan

[14] Tokai Univ, Dept Pathol, Isehara, Kanagawa, Japan

[15] Kanagawa Canc Ctr, Dept Med Oncol, 1-1-2 Nakao, Yokohama, Kanagawa 2410815, Japan

[16] Nagoya Univ Hosp, Dept Pathol, Nagoya, Aichi, Japan

[17] Nagoya Univ Hosp, Clin Labs, Nagoya, Aichi, Japan

[18] Aichi Canc Ctr, Dept Hematol & Cell Therapy, Nagoya, Aichi 464, Japan

[19] Tokai Cent Hosp, Dept Hematol, Kakamigahara, Japan

来源：

BLOOD CANCER JOURNAL | 2015年 / 5卷

关键词：

RITUXIMAB; THERAPY;

D O I：

10.1038/bcj.2015.101

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：e372 / e372

页数：5

共 15 条

[1] Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan [J].

Aoki, Tomohiro ;

Izutsu, Koji ;

Suzuki, Ritsuro ;

Nakaseko, Chiaki ;

Arima, Hiroshi ;

Shimada, Kazuyuki ;

Tomita, Akihiro ;

Sasaki, Makoto ;

Takizawa, Jun ;

Mitani, Kinuko ;

Igarashi, Tadahiko ;

Maeda, Yoshinobu ;

Fukuhara, Noriko ;

Ishida, Fumihiro ;

Niitsu, Nozomi ;

Ohmachi, Ken ;

Takasaki, Hirotaka ;

Nakamura, Naoya ;

Kinoshita, Tomohiro ;

Nakamura, Shigeo ;

Ogura, Michinori .

HAEMATOLOGICA, 2014, 99 (12) :1817-1825

[2] Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma [J].

Dunleavy, Kieron ;

Pittaluga, Stefania ;

Maeda, Lauren S. ;

Advani, Ranjana ;

Chen, Clara C. ;

Hessler, Julie ;

Steinberg, Seth M. ;

Grant, Cliona ;

Wright, George ;

Varma, Gaurav ;

Staudt, Louis M. ;

Jaffe, Elaine S. ;

Wilson, Wyndham H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (15) :1408-1416

[3] Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era [J].

Gisselbrecht, Christian ;

Glass, Bertram ;

Mounier, Nicolas ;

Gill, Devinder Singh ;

Linch, David C. ;

Trneny, Marek ;

Bosly, Andre ;

Ketterer, Nicolas ;

Shpilberg, Ofer ;

Hagberg, Hans ;

Ma, David ;

Briere, Josette ;

Moskowitz, Craig H. ;

Schmitz, Norbert .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4184-4190

[4] Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma [J].

Han, Li-na ;

Zhou, Jin ;

Hirose, Takayuki ;

Imai, Yosuke ;

Ishiguro, Takuro ;

Chou, Takaaki .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2006, 84 (02) :174-181

[5] Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression [J].

Jacobsen, Eric D. ;

Sharman, Jeff P. ;

Oki, Yasuhiro ;

Advani, Ranjana H. ;

Winter, Jane N. ;

Bello, Celeste M. ;

Spitzer, Gary ;

Palanca-Wessels, Maria Corinna ;

Kennedy, Dana A. ;

Levine, Pamela ;

Yang, Jing ;

Bartlett, Nancy L. .

BLOOD, 2015, 125 (09) :1394-1402

[6] Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma [J].

Kamezaki, K. ;

Kikushige, Y. ;

Numata, A. ;

Miyamoto, T. ;

Takase, K. ;

Henzan, H. ;

Aoki, K. ;

Kato, K. ;

Nonami, A. ;

Kamimura, T. ;

Arima, F. ;

Takenaka, K. ;

Harada, N. ;

Fukuda, T. ;

Hayashi, S. ;

Ohno, Y. ;

Eto, T. ;

Harada, M. ;

Nagafuji, K. .

BONE MARROW TRANSPLANTATION, 2007, 39 (09) :523-527

[7] Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma [J].

Kuruvilla, John ;

Pintilie, Melania ;

Tsang, Richard ;

Nagy, Tracy ;

Keating, Armand ;

Crump, Michael .

LEUKEMIA & LYMPHOMA, 2008, 49 (07) :1329-1336

[8] [18F] Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study [J].

Martelli, Maurizio ;

Ceriani, Luca ;

Zucca, Emanuele ;

Zinzani, Pier Luigi ;

Ferreri, Andres J. M. ;

Vitolo, Umberto ;

Stelitano, Caterina ;

Brusamolino, Ercole ;

Cabras, Maria Giuseppina ;

Rigacci, Luigi ;

Balzarotti, Monica ;

Salvi, Flavia ;

Montoto, Silvia ;

Lopez-Guillermo, Armando ;

Finolezzi, Erica ;

Pileri, Stefano A. ;

Davies, Andrew ;

Cavalli, Franco ;

Giovanella, Luca ;

Johnson, Peter W. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (17) :1769-U45

[9] Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: Role of rituximab, high-dose therapy, and allogeneic stem cell transplantation [J].

Nath, SV ;

Seymour, JF .

LEUKEMIA & LYMPHOMA, 2005, 46 (07) :1075-1079

[10] Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study [J].

Rieger, M. ;

Osterborg, A. ;

Pettengell, R. ;

White, D. ;

Gill, D. ;

Walewski, J. ;

Kuhnt, E. ;

Loeffler, M. ;

Pfreundschuh, M. ;

Ho, A. D. .

ANNALS OF ONCOLOGY, 2011, 22 (03) :664-670

← 1 2 →